Terms: = Endocrine gland cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras
1434 results:
1. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant k-ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
2.
Sfreddo HJ; Koh ES; Zhao K; Swartzwelder CE; Untch BR; Marti JL; Roman BR; Dublin J; Wang RS; Xia R; Cohen JM; Xu B; Ghossein R; Givi B; Boyle JO; Tuttle RM; Fagin JA; Wong RJ; Morris LGT
Thyroid; 2024 Apr; 34(4):450-459. PubMed ID: 38407967
[No Abstract] [Full Text] [Related]
3. Identification of Germline
Pires C; Saramago A; Moura MM; Li J; Donato S; Marques IJ; Belo H; Machado AC; Cabrera R; Grünewald TGP; Leite V; Cavaco BM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396644
[TBL] [Abstract] [Full Text] [Related]
4. k-ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
[TBL] [Abstract] [Full Text] [Related]
5. The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms.
Canberk S; Gonçalves J; Rios E; Povoa AA; Tastekin E; Sobrinho-Simões M; Uguz A; Aydin O; Ince U; Soares P; Máximo V
Endocr Pathol; 2024 Mar; 35(1):25-39. PubMed ID: 38285158
[TBL] [Abstract] [Full Text] [Related]
6. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract] [Full Text] [Related]
7. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
8. k-ras gene mutation analysis to diagnosis pancreatic adenocarcinoma from endoscopic ultrasound-guided tissue acquisition; a systematic review and meta-analysis.
Tamura T; Ashida R; Wan K; Shimokawa T; Kitano M
Pancreatology; 2024 Feb; 24(1):78-87. PubMed ID: 38042675
[TBL] [Abstract] [Full Text] [Related]
9. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
[TBL] [Abstract] [Full Text] [Related]
10. Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer.
Rowell MC; Deschênes-Simard X; Lopes-Paciencia S; Le Calvé B; Kalegari P; Mignacca L; Fernandez-Ruiz A; Guillon J; Lessard F; Bourdeau V; Igelmann S; Duman AM; Stanom Y; Kottakis F; Deshpande V; Krizhanovsky V; Bardeesy N; Ferbeyre G
Cell Cycle; 2023 Oct; 22(19):2172-2193. PubMed ID: 37942963
[TBL] [Abstract] [Full Text] [Related]
11. Regulation of epinephrine biosynthesis in hras-mutant paragangliomas.
Li M; Richter S; Mohr H; Drukewitz S; Poser I; Stanke D; Calsina B; Martinez-Montes AM; Quinkler M; Timmers HJLM; Nölting S; Beuschlein F; Remde H; Opocher G; Rapizzi E; Pacak K; Pamporaki C; Robledo M; Liu L; Jiang J; Bornstein SR; Eisenhofer G; Fliedner SMJ; Bechmann N
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902037
[TBL] [Abstract] [Full Text] [Related]
12. Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer.
Briseño-Díaz P; Schnoor M; Bello-Ramirez M; Correa-Basurto J; Rojo-Domínguez A; Arregui L; Vega L; Núñez-González E; Palau-Hernández LA; Parra-Torres CG; García Córdova OM; Zepeda-Castilla E; Torices-Escalante E; Domínguez-Camacho L; Xoconostle-Cazares B; Meraz-Ríos MA; Delfín-Azuara S; Carrión-Estrada DA; Villegas-Sepúlveda N; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37813486
[TBL] [Abstract] [Full Text] [Related]
13. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Pitfall in Thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
14. The inhibition of pancreatic cancer progression by k-ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
15. A new ferrocene derivative blocks k-ras localization and function by oxidative modification at His95.
Rehl KM; Selvakumar J; Pitsch RL; Hoang D; Arumugam K; Harshman SW; Gorfe AA; Cho KJ
Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37666666
[TBL] [Abstract] [Full Text] [Related]
16. Nimotuzumab Plus Gemcitabine for k-ras Wild-Type Locally Advanced or Metastatic Pancreatic cancer.
Qin S; Li J; Bai Y; Wang Z; Chen Z; Xu R; Xu J; Zhang H; Chen J; Yuan Y; Liu T; Yang L; Zhong H; Chen D; Shen L; Hao C; Fu D; Cheng Y; Yang J; Wang Q; Qin B; Pan H; Zhang J; Bai X; Zheng Q
J Clin Oncol; 2023 Nov; 41(33):5163-5173. PubMed ID: 37647576
[TBL] [Abstract] [Full Text] [Related]
17. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
[TBL] [Abstract] [Full Text] [Related]
18. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract] [Full Text] [Related]
19. Non-hyalinizing trabecular thyroid adenoma: a novel thyroid tumor with diagnostic pitfalls of hyalinizing trabecular adenoma and medullary thyroid carcinoma.
Hirokawa M; Matsuse M; Mitsutake N; Suzuki A; Higuchi M; Hayashi T; Kamma H; Miyauchi A; Akamizu T
Diagn Pathol; 2023 Jun; 18(1):74. PubMed ID: 37340328
[TBL] [Abstract] [Full Text] [Related]
20. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
[TBL] [Abstract] [Full Text] [Related]
[Next]
